Program
safusidenib
Also written as “Safusidenib”, “DS-1001b” and “AB-218 capsule”.
Its studies are mostly in Glioma · Oligodendroglioma · Astrocytoma · Cholangiocarcinoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nuvation Bio | 43 open or running | phase 3since Mar 13, 2022 | Mar 13, 2022 | Dec 1, 2028phase 3 · NCT05303519 |
| Daiichi Sankyo | 21 open or running | phase 2since Jun 29, 2020 | Jan 18, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 18, 2017First study: phase 1 study in GliomaNew to Daiichi SankyoDaiichi Sankyo · NCT03030066 · 47 enrolled · Japan
- Jun 29, 2020Phase 2 study in GliomaDaiichi Sankyo · NCT04458272 · 25 enrolled · Japan
- Mar 13, 2022Nuvation Bio’s first study: phase 3 study in GliomaNew to Nuvation BioNuvation Bio · NCT05303519 · 365 planned · United States, Australia, China
- Mar 20, 2023Phase 1 study in Cholangiocarcinoma With IDH1 MutationNuvation Bio · NCT05814536 · 9 enrolled · China
- Jul 9, 2026Phase 3 study in AstrocytomaNuvation Bio · NCT07712757 · 140 planned
- Jul 9, 2026Phase 2 study in GliomaNuvation Bio · NCT07703436 · 40 planned · United States
Ahead
- Dec 1, 2028Primary completion: phase 3 study in GliomaNuvation Bio · NCT05303519
- May 2029Primary completion: phase 3 study in AstrocytomaNuvation Bio · NCT07712757
- Sep 2030Primary completion: phase 2 study in GliomaNuvation Bio · NCT07703436
TargetBeta
“An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, including substitution mutations at the arginine in position 132, IDH1(R132) (IDH1-R132), ”NCIt, by rule
“Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule
Other programs on IDH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olutasidenibrule | Rigel Pharmaceuticals | phase 4 | 5 |
| ivosidenibrule | Agios Pharmaceuticals | phase 3 | 13 |
| vorasidenibrule | Agios Pharmaceuticals | phase 3 | 12 |
| ranosidenibrule | HUTCHMED | phase 3 | 7 |
| IDH1 Inhibitor TQB3454 | Sino Biopharmaceutical | phase 3 | 5 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07712757Astrocytoma | 3 | Not yet recruiting | Nuvation Bio | May 2029 | 140 |
| NCT07703436Glioma · United States | 2 | Recruiting | Nuvation Bio | Sep 2030 | 40 |
| NCT05814536Cholangiocarcinoma With IDH1 Mutation · China | 1 | Terminated | Nuvation Bio | Aug 15, 2024 | 9 |
| NCT05303519Glioma · United States, Australia, China | 3 | Recruiting | Nuvation Bio | Dec 1, 2028 | 365 |
| NCT04458272Glioma · Japan | 2 | Active, not recruiting | Daiichi Sankyo | Mar 10, 2023 | 25 |
| NCT03030066Glioma · Japan | 1 | Completed | Daiichi Sankyo | Jan 31, 2021 | 47 |
How it is read
Names in the registry
- “Safusidenib”, 2 entries
- “DS-1001b”, 2 entries
- “safusidenib”, 1 entry
- “AB-218 capsule”, 1 entry
Conditions, from the studies’ own filings
- Glioma, 3 studies
- Oligodendroglioma, 1 study
- Astrocytoma, 1 study
- Cholangiocarcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.